Abstract
Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best supportive care. Nevertheless, as the overall survival remains disappointing, clinical research must ongoing to define better treatment regimen.
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Gemcitabine
-
Humans
-
Palliative Care*
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / surgery
-
Prognosis
-
Quality of Life
-
Randomized Controlled Trials as Topic
-
Survival Analysis
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Gemcitabine